Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2018
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms OPTIMABI
- 31 Aug 2018 Biomarkers information updated
- 10 Aug 2018 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 10 Aug 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.